Translational tidbits

Amgen Inc. is teaming up with researchers at Massachusetts General Hospital and the Broad Institute of MIT and Harvard to find new targets in inflammatory bowel disease. The partners hope an unbiased search for genetic variants that lower risk of the autoimmune disorder will uncover therapeutic entry points.

Amgen will work with teams led by Ramnik Xavier, chief of gastroenterology and director of the Center for the Study of Inflammatory Bowel Disease at MGH, and Mark Daly, an associate professor of medicine at MGH. Xavier and Daly are both senior associate members of the Broad Institute...